The Future is Faster Than You Think - Peter Diamandis
1. META-TRENDS
Peter H. Diamandis, MD
The Future Is Faster Than You Think
How Converging Technologies Are
Transforming Business, Industries & Our Lives
2. We are living during the
most extraordinary time in
human history
3. “People have no idea how
fast things are changing.”
- Undisclosed Silicon Valley CEO
27. 2019 PHD Ventures A360 LLC. All rights reserved. Do not reproduce without written permission.
AMAZON PROJECT KUIPER: 3,236 SATELLITES
“$100 billion opportunity.” – Morgan Stanley
31. 2019 PHD Ventures A360 LLC. All rights reserved. Do not reproduce without written permission.
2020: 20B+ connected devices & >1 Trillion Sensors
2030: 500B+ connected devices & >100 Trillion Sensors
It’s not just people being connected, we are
connecting everything, everywhere…
IoT TO CREATE $6.2 TRILLION OF NEW ECONOMIC
VALUE BY 2025 - McKinsey
40. Introducing Rival Theory’s
“AI Persona”
• Digital representations of real people
• Unlimited in their ability to connect and interact
• Across millions of simultaneous conversations
41. Rival Theory’s PERSONA’s Capabilities:
Human knowledge: AI Persona learn and understand information
through reading, observation, and human
interaction. Not just “what” but “how” and “why”.
Of real people: AI Persona are created by modeling the thoughts,
emotions, behaviors, and mannerisms of real
human beings.
At global scale: AI Persona can represent the knowledge, beliefs,
and expertise of a human, but do so
exponentially, having millions of simultaneous
conversations around the world.
42. Supporting Your Employees:
• Just-in-time Mentorship & Coaching
• Just-in-time skill acquisition for
problem solving
• Improved education & creativity
• Increased situational intelligence,
efficiency and productivity
• Enhance quality of life
HUMAN
+
DIGITAL
43.
44. Timelines & Scale
Q2 2020: First commercial AI Persona of renowned
author, speaker, and entrepreneur Tony
Robbins expected to launch in Q2 2020.
9 months: Time to create an AI Persona based on a real
person, including voice and visual models (will
reduce to 3 months time by Q3 2020).
1 million: Expected number of simultaneous AI Personas
engaged with users by Q1 2021
45. • Bryan Johnson/Kernel
• Elon Musk/Neuralink
• OpenWater
• Facebook
• Google
• IBM
• BrainGate
• Paradromics
• DARPA
• …China Co.
• …Russia Co.
2035
Just In Time Knowledge & Intelligence
50. Actionable Results from 1,253 “healthy” Clients
2%
2%
3.4%
14.8%
84% & 17%
43%
19%
84% Genetic carriers for recessive
diseases. 17% have a genetic
mutation that affects their health.
Elevated liver fat, mostly non-
alcoholic fatty liver disease &
increased visceral abdominal fat.
Moderate atherosclerotic coronary
calcifications
Brain or aortic aneurysm
Tumor /high grade
cancers and early stage.
Newly found Atrial
fibrillation, BBB, or high
grade AV block
Aberrant cardiac
structure/function
findings
14.4%: Have significant findings that
require immediate follow-up/action.
40%: Have findings that have Long-term
value to your medical treatments.
51. CFU-F/106MNCs
350
300
250
200
150
100
50
0
0 10 20 30 40 50 60 70
R2 = 0.51
Drs. Hariri & Caplan showed: Number of stem cells in our body diminish 100x –
1000x; The stem cells undergo epigenetic changes and loose their effectiveness.
WHY DO WE AGE?
Loss of Stem Cell Quantity and Quality with Age
52. Confidential – Not for Distribution
Restores physio-anatomic
performance during
aging.
Restores organ and tissue
functionality, enhance
human performance and
improve wellness
Replenishing the reservoir
of high quality stem cells…
Confidential Briefing / DO NOT DISTRIBUTE
53. 2019 PHD Ventures A360 LLC. All rights reserved. Do not reproduce without written permission.
In the U.S., there are 1M+ people living with end stage organ
diseases in need of new hearts, kidneys, lungs, etc.
UNITED THERAPUTICS 3D PRINTS LUNGS
54. 2019 PHD Ventures A360 LLC. All rights reserved. Do not reproduce without written permission.
SENOLYTIC DRUGS EXTEND LIFESPAN OF
MICE 30% -- NOW IN HUMAN TESTING
55. 2019 PHD Ventures A360 LLC. All rights reserved. Do not reproduce without written permission.
SAMUMED REACHED $12 BILLION VALUATION
TARGETS AGING VIA THE WNT PATHWAY
Preclinical à Phase-1 à Phase-2 à Phase-3
Solid Tumor/Oncology Phase 1 Trial
Alzheimer’s Disease Phase 1 Trial
Degenerative Disc Disease Phase 1 Trial
Tendinopathy Phase 2 Trial
Idiopathic Pulmonary Fibrosis Phase 2 Trial
Osteoarthritis Treatment Phase 3 Trial
Hair Loss (Androgenic Alopecia) Phase 3 Trial